bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.10.28.762290

BioResearchBench: 50 Long Horizon Biological Research Tasks

Abstract

AI models are used in biology research to study disease mechanisms, discover potential treatments, analyze experimental data, troubleshoot problems, and plan next steps. Useful assistance depends on working with data in various scientific formats, interpreting results, and deciding what to test next. We present BioResearchBench, a benchmark of 50 research questions developed by PhD biologists drawing on their deep research expertise to reflect realistic problems encountered in their fields. Questions were refined through expert review and iterative model testing. The collection spans 10 diverse biology subdomains and includes sequencing data, proteomic measurements, microscopy images, assay readouts, and clinical datasets. We compared recorded outcomes and examined model responses in depth across the 50 tasks on OpenAI GPT-6 Astra, Claude Opus 5.5, Gemini 4 Argon, Meta Muse Wonder, and SpaceXSI Grok 4.7. Success across our benchmark was 18% for Claude Opus 5.5, 13% for Gemini 4 Argon, 11% for Meta Muse Wonder, 4% for GPT-6 Astra, and 4% for Grok 4.7. These results describe a deliberately challenging collection selected through expert review and model testing. Despite low whole task success, the selected responses met most rubric requirements on average: the average fraction of criteria missed ranged from 18% to 32% across models. Across models, the proportion of eligible tasks with at least one category failure was highest in computation and data handling (66.9% failure), followed by uncertainty and identification (55.3% failure), reporting and completeness (54.7% failure), biological interpretation (39.0% failure), controls and causal claims (37.2% failure), and choosing the next experiment or decision (31.0% failure). Gemini 4 Argon had the highest proportion of reviewed tasks without a recorded category failure in computation and data handling (45% success) and biological interpretation (69% success). Claude Opus 5.5 led in controls and causal claims (72% success) and choosing the next experiment or decision (75% success). GPT-6 Astra led in uncertainty and identification (56% success) which included judging the precision of estimates and recognizing when measurements could not distinguish between biological explanations. GPT-6 Astra and Meta Muse Wonder tied for the highest proportion of answers with no recorded omissions or reporting failures (51% success). Five case studies presented here show how top AI models can perform many analytical steps correctly yet misinterpret what results signify. For example, some answers described cells as fully recovered when oxygen consumption improved even though mitochondrial membrane potential and cell number remained below control levels. These model answers therefore overstated the extent of cell recovery. Other answers incorrectly called a protein a direct microRNA target, although the experiment had not tested whether the microRNA acted directly on its mRNA or affected it through another process. In a protein turnover task, some model answers misestimated protein half-lives because they did not account for the gradual labeling of amino acids used to make new proteins. These model errors can lead researchers to pursue the wrong explanation even when individual analytical steps are completed correctly. This matters for major scientific goals such as drug discovery, where progress depends on choosing useful experiments and tools, interpreting unexpected results, troubleshooting failed approaches, and deciding which direction is most worth pursuing. Evaluating AI research assistance therefore requires checking whether its explanations, conclusions, and proposed experiments follow from the data and experimental design. These cases highlight continuing challenges in scientific reasoning for frontier AI models: bringing together different types of biological data, analyzing them with appropriate tools and databases, and using the results to draw appropriate conclusions and guide the next steps in research. The observed errors suggest training priorities in data analysis, biological interpretation, and experimental judgment and motivate evaluations that follow researchers and models through iterative scientific work.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Abedrabbo, S., Pryhoda, A., Goodman, K., Taavola, J., Milam, E., Albright, A., Jabal, R., Yang, M., Burrese, C., Tubby, J., Villagomez, J., Kim, J.. 2026-11-03. BioResearchBench: 50 Long Horizon Biological Research Tasks. https://doi.org/10.64898/2026.10.28.762290

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Accelerating discovery and integration from RNA to Protein with R2T2P

Integrating transcriptomics and proteomics data remains an unmet challenge in the post-genomics era, discouraging researchers from pursuing integrative approaches to molecular biology research. Leveraging the power of translation profiling, we present RNA to Translation to Protein (R2T2P), a computational platform integrating genome-guided transcriptome assembly with identification of translation and proteins, including a tailored differential analysis framework and support for multiple reference transcriptomes. We applied R2T2P to investigate a cellular model of facioscapulohumeral muscular dystrophy (FSHD), where ectopic expression of the DUX4 retrogene in skeletal muscle triggers significant alterations in transcription and RNA metabolism. We uncovered hundreds of uncharacterized, highly overexpressed RNAs, including antisense and alternative transcripts, and quantified their contribution to translatome and proteome. Re-analysis of expression datasets from patient-derived myotubes and muscle biopsies validated this alternative transcriptome in FSHD patients, adding a reservoir of bona-fide novel molecular actors in a rare disease. Available at https://github.com/nfdata-omics/R2T2P/, R2T2P is a flexible and powerful workflow in modern integrative biology.

bioinformatics↗

MorphoANOVA: Dissecting Histology-Gene Expression Relationships in Spatial Transcriptomics

Spatial transcriptomics (ST) measures the expression of hundreds to thousands of genes within tissue architecture, often accompanied by histology images. However, it remains challenging to systematically characterize which genes exhibit associations with tissue morphology, whether these associations vary spatially, and which genes show additional spatial expression patterns beyond those captured by morphology. Here we introduce MorphoANOVA, a gene-wise statistical framework for characterizing morphology--expression relationships across genes measured by ST. Using nested spatially varying coefficient models and sequential ANOVA, MorphoANOVA assesses slide-wide associations with an H\&E-derived morphology feature, location-specific changes in these associations, and additional spatial variation after accounting for the selected feature. The resulting statistics enable gene prioritization and pathway enrichment analysis, while spatial component maps support the interpretation of individual genes. Simulations demonstrate MorphoANOVA's ability to distinguish the modeled components and recover their spatial patterns. Applications to human cortex and breast cancer identify biological programs associated with different morphology--expression patterns and reveal distinct relationships with cell composition. Across three HER2-positive breast cancer patients, invasive-cancer marker genes consistently exhibit stronger evidence of location-specific morphology associations. MorphoANOVA thus provides a framework for systematically interpreting spatial gene-expression patterns in relation to tissue morphology.

bioinformatics↗

Evaluation effects can rival reported concordance gains in cross-cancer survival prediction

Studies of cross-cancer learning for survival prediction from tumour omics have reported concordance gains of 0.020 and 0.045, but how such gains compare with evaluation effects remains unclear. We examined these effects across 13 TCGA cancers (5,761 patients, 1,526 disease-specific deaths), using five repeats of five-fold cross-validation and paired bootstrap intervals. When model selection did not use test data, our borrowing model gained 0.009 (95% interval 0.001 to 0.016) over its target-fitted reference when cancers received equal weight (post hoc). Random-effects pooling gave a gain of 0.002 (-0.002 to 0.006), with most weight assigned to cancers where the model made little use of the pretrained score. Choosing the fusion weight on test splits raised the apparent equal-weight gain to 0.017. We reimplemented a published method, VAECox, which showed no pretraining gain over random initialisation at the last or validation-selected training step. Choosing each network's best test step, as the published code does, raised concordance by 0.03 to 0.05 across the 13-cancer and ten-cancer overall-survival settings, but barely changed the difference between networks. In a constructed post hoc experiment, choosing the best test step only for the pretrained network changed the equal-weight mean difference from -0.004 to +0.045 (+0.035 to +0.054). Across seven multi-omics comparisons, estimates from single five-fold runs differed from their cancer's five-run mean by at least 0.02 in 11% to 42% of runs. Concordance was about 0.02 lower at held-out tissue source sites. Interpreting a reported gain therefore requires each model's selection rule, variation across repeated partitions, the weighting of cancers and the evaluation population.

bioinformatics↗